Allogenic Blood Transfusion During Elective Open Abdominal Aortic Surgery

Status Completed

Clinical Trial Summary

Open surgery on the abdominal aorta is a high risk procedure associated with an intravascular volume blood loss and thereby, with high requirement for blood and blood product transfusion.

The aim of this study was to establish the rate for allogenic blood transfusion (ABT) during elective open abdominal aortic surgery and find parameters associated with ABT requirements.

Clinical Trial Description

Two distinct clinical entities affect the abdominal aorta: abdominal aortic aneurysm (AAA) and aortoiliac occlusive disease (AIOD). These are multifactorial vascular disorders caused by complex genetic and environmental factors. Older patients with more comorbidity are often affected. Open abdominal aortic surgery is associated with high mortality rate. Even in specialised institutions it varies from 2 to 5%. Similar results can be compared to mortality for coronary artery bypass grafting. This reflects the complexity of the surgery and the general health of those patients. It is associated with intravascular volume blood loss and, thereby, with a high requirement for blood and blood products transfusion. Allogenic blood transfusion (ABT) has been associated with an increased risk of tumour recurrence, postoperative infection, acute lung injury, perioperative myocardial infarction, postoperative low-output cardiac failure, and increased mortality.

In the last decades, multiple strategies have been undertaken to prevent massive intraoperative blood loss during elective surgery and allogenic blood transfusion requirement. One of the method advocates a preoperative increase in red blood cells level using B12, folic acid and iron supplements or with erythropoietin usage. Other methods involve the optimisation of surgical technique and the use of a machine for intraoperative blood salvage, known as "cell saver".

The aim of this study was to establish the rate for ABT during elective open abdominal aortic surgery, find parameters associated with ABT requirements, and optimise the investigators hospital's maximum surgical blood ordering schedule (MSBOS). ;

Study Design

Related Conditions & MeSH terms

Blood Transfusion

Clinical Trial Details

NCT number	NCT03891303
Study type	Observational
Source	Clinic for Cardiovascular Diseases Magdalena
Contact
Status	Completed
Phase
Start date	January 1, 2011
Completion date	October 15, 2018

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03651154` - Hypovolemic Phlebotomy to Reduce Blood Transfusions in Major Hepatic Resections	N/A
Completed	`NCT01136590` - Multicenter, Randomized Placebo-controlled Clinical Trial to Evaluate the Effect of Perioperative Use of Tranexamic Acid on Transfusion Requirements and Surgical Bleeding in Major Spine Surgery	Phase 4
Completed	`NCT00097006` - Retrovirus Epidemiology Donor Study-II (REDS-II)	N/A
Completed	`NCT00005303` - Effectiveness of AIDS Antibody Screening	N/A
Completed	`NCT00005319` - Epidemiologic Studies of Blood Use in the United States - SCOR in Transfusion Medicine	N/A
Completed	`NCT00005301` - Transfusion Safety Study (TSS)	N/A
Completed	`NCT00000581` - Granulocyte Transfusion Study	Phase 3
Completed	`NCT04089865` - Oral Versus Intravenous Tranexamic Acid	Phase 4
Completed	`NCT02968654` - TRansfusion Strategies in Acute Brain INjured Patients	N/A
Enrolling by invitation	`NCT06019364` - Transfusion of Whole Blood in Acute Bleeding
Completed	`NCT04911413` - Comparison of Three Tranexamic Acid Dose Regimens in Patients Undergoing Cardiac Valve Surgery	Phase 4
Completed	`NCT03727230` - RhD+ Blood Transfusion to Asian-type DEL Recipients	N/A
Recruiting	`NCT06102590` - Oxygen Extraction-guided Transfusion	N/A
Completed	`NCT00400192` - Transfusion-Associated Microchimerism in Individuals Receiving a Blood Transfusion After a Traumatic Injury	N/A
Completed	`NCT00000593` - Viral Activation Transfusion Study (VATS)	N/A
Completed	`NCT05581238` - Validation of a Red Blood Cell Transfusion Prediction Model in a Low Transfusion Rate Population.
Completed	`NCT05627544` - Blood Transfusion Applications in Hip Replacements
Not yet recruiting	`NCT03429790` - Cell Salvage During Caesarean Section (CSCS)	N/A
Completed	`NCT00822588` - Comparison in Need for Bank Blood Between Patients Undergoing Total Hip Surgery That Either Receive Their Own Blood Back or Not	N/A
Withdrawn	`NCT00269971` - A Study to Determine an Effective Dose of Epoetin Alfa to Decrease the Number of Units of Blood Required to be Transfused During Hip Replacement Surgery.	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.